What is Claimed:

1. Crystalline (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide hydrochloride salt monohydrate Form A characterized by a powder x-ray diffraction pattern comprising 2θ values (CuKα, 40 KV, 40 mA) 14.7 ± 0.2, 16.5 ± 0.2, 17.6 ± 0.2, 23.5 ± 0.2 and 24.3 ± 0.2.

2. Crystalline (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide hydrochloride salt according to claim 1, characterized by a powder X-ray diffraction pattern comprising the 2θ values (CuKα, 40 KV, 40 mA) 8.9 ± 0.2, 10.1 ± 0.2, 11.7 ± 0.2, 13.5 ± 0.2, 13.9 ± 0.2, 14.7 ± 0.2, 15.2 ± 0.2, 15.4 ± 0.2, 16.5 ± 0.2, 17.6 ± 0.2, 19.2 ± 0.2, 19.4 ± 0.2, 20.3 ± 0.2, 21.1 ± 0.2, 21.6 ± 0.2, 22.4 ± 0.2, 23.5 ± 0.2, 24.3 ± 0.2, 25.7 ± 0.2, 26.1 ± 0.2, 26.6 ± 0.2, 27.0 ± 0.2, 28.2 ± 0.2, 29.0 ± 0.2, 29.8 ± 0.2, 30.6 ± 0.2, 31.2 ± 0.2 and 32.0 ± 0.2.

3. Crystalline (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide anhydrous hydrochloride salt Form B characterized by a powder x-ray diffraction pattern comprising the 2θ values (CuKα, 40 KV, 40 mA) 13.0 ± 0.2, 14.2 ± 0.2, 16.3 ± 0.2, 18.5 ± 0.2, 21.0 ± 0.2, 23.9 ± 0.2 and 24.7 ± 0.2.

4. Crystalline (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide hydrochloride salt according to claim 3, characterized by a powder X-ray diffraction pattern comprising the 2θ values (CuKα, 40 KV, 40 mA) 8.7 ± 0.2, 10.0 ± 0.2, 11.6 ± 0.2, 11.9 ± 0.2, 13.0 ± 0.2, 14.2 ± 0.2, 15.5 ± 0.2, 16.3 ± 0.2, 17.4 ± 0.2, 18.5 ± 0.2, 19.2 ± 0.2, 20.0 ± 0.2, 20.3 ± 0.2, 21.0 ± 0.2, 21.7 ± 0.2, 21.9 ± 0.2, 22.7 ± 0.2, 23.2 ± 0.2, 23.9 ± 0.2, 24.7 ± 0.2, 25.4 ± 0.2, 26.1 ± 0.2, 26.8 ± 0.2, 27.2 ± 0.2, 28.0 ± 0.2, 28.4 ± 0.2, 29.2 ± 0.2, 29.8 ± 0.2, 30.2 ± 0.2 and 30.9 ± 0.2.

5. A compound according to any one of claims 1-4, or any combination thereof for use in treating cancer in a patient in need of such treatment, wherein a therapeutically effective amount of the compound is to be administered to the patient.

6. Use of compound according to any one of claims 1-4, or any combination thereof in the manufacture of a medicament for treating cancer in a patient in need of such treatment, wherein a therapeutically effective amount of the compound is to be administered to the patient.

7. The compound for use of claim 5 or the use of claim 6, wherein the cancer is a cancer of the prostate, colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin (including melanoma and basal carcinoma), mesothelial lining, white blood cell (including lymphoma and leukemia), esophagus, breast, muscle, connective tissue, lung (including small-cell lung carcinoma and non-small-cell carcinoma), adrenal gland, thyroid, kidney, or bone; or is glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma (including Kaposi's sarcoma), choriocarcinoma, cutaneous basocellular carcinoma, or testicular seminoma.

8. The compound for use of claim 5 or the use of claim 6, wherein an immune checkpoint inhibitor is to be further administered with the compound.

9. The compound for use or the use of claim 8, wherein the immune checkpoint inhibitor is ipilimumab (YERVOY™), nivolumab (OPDIVO™), pembroluzimab (KEYTRUDA™), or a combination thereof.

10. A method of modulating the activity of indoleamine 2,3-dioxygenase comprising contacting the indoleamine 2,3-dioxygenase with a compound according to any one of claims 1-4, or any combination thereof.